$CELC· SEC filing ·

CELC Reports $1.2M Q4 Rev, $0.01 EPS, FDA Accepts NDA for Gedatolisib, Priority Review July 2026, VIKTORIA-1 Topline Data Q2 2026

Celcuity Inc. Common Stock · SERVICES-MEDICAL LABORATORIES · Now $122.96

Post-detection moves

1h
1d
3d
7d
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS